151 related articles for article (PubMed ID: 29559345)
1. Selective Use of Cyclosporine for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis May Exclude Patients with Poor Prognostic Factors.
Noe MH; Mostaghimi A; Rosenbach M; Shinkai K; Micheletti RG
J Invest Dermatol; 2018 Sep; 138(9):2068-2072. PubMed ID: 29559345
[No Abstract] [Full Text] [Related]
2. Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study.
Mohanty S; Das A; Ghosh A; Sil A; Gharami RC; Bandyopadhyay D; Das NK
Indian J Dermatol Venereol Leprol; 2017; 83(3):312-316. PubMed ID: 28366923
[TBL] [Abstract][Full Text] [Related]
3. FR-Ciclosporin as a First-Line Treatment in Epidermal Necrolysis.
Morgado-sCarrasco D; Fustà-Novell X; Iranzo P
Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):601-603. PubMed ID: 30971332
[No Abstract] [Full Text] [Related]
4. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
Valeyrie-Allanore L; Wolkenstein P; Brochard L; Ortonne N; Maître B; Revuz J; Bagot M; Roujeau JC
Br J Dermatol; 2010 Oct; 163(4):847-53. PubMed ID: 20500799
[TBL] [Abstract][Full Text] [Related]
5. Intravenous cyclosporine in treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series.
Vinay K; Kaushik A; Kumaran MS; Parsad D
Dermatol Ther; 2019 Jul; 32(4):e12957. PubMed ID: 31070856
[No Abstract] [Full Text] [Related]
6. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.
Kirchhof MG; Miliszewski MA; Sikora S; Papp A; Dutz JP
J Am Acad Dermatol; 2014 Nov; 71(5):941-7. PubMed ID: 25087214
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis at the University Hospital of the West Indies, Jamaica.
East-Innis AD; Thompson DS
West Indian Med J; 2013 Sep; 62(7):589-92. PubMed ID: 24831894
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective.
Gupta LK; Martin AM; Agarwal N; D'Souza P; Das S; Kumar R; Pande S; Das NK; Kumaresan M; Kumar P; Garg A; Singh S
Indian J Dermatol Venereol Leprol; 2016; 82(6):603-625. PubMed ID: 27716721
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
10. RF - Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Treatment Update.
de Quintana-Sancho A; Rubio-Lombraña M; Guergue Díaz-de-Cerio O; Barrutia-Borque A
Actas Dermosifiliogr; 2016 Apr; 107(3):247-8. PubMed ID: 26138285
[No Abstract] [Full Text] [Related]
11. Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis.
Rai R; Srinivas CR
Indian J Dermatol Venereol Leprol; 2008; 74(3):263-5. PubMed ID: 18583801
[No Abstract] [Full Text] [Related]
12. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
13. Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate.
Hashim N; Bandara D; Tan E; Ilchyshyn A
Acta Derm Venereol; 2004; 84(1):90-1. PubMed ID: 15040495
[No Abstract] [Full Text] [Related]
14. [Factors associated with the severity of acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa].
Saka B; Dzidzinyo K; Akakpo S; Téclessou J; Nouhou Diori A; Maneh N; Mahamadou G; Gnassingbé W; Abilogun-Chokki A; Mouhari-Toure A; Boubacar YA; Kombaté K; Balo K; Tchangai-Walla K; Pitché P
Ann Dermatol Venereol; 2018 Apr; 145(4):245-249. PubMed ID: 29487020
[TBL] [Abstract][Full Text] [Related]
15. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
16. Use of cyclosporine for the treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Shah R; Chen ST; Kroshinsky D
J Am Acad Dermatol; 2021 Aug; 85(2):512-513. PubMed ID: 30630021
[No Abstract] [Full Text] [Related]
17. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS
Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523
[TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.
Schneider JA; Cohen PR
Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852
[TBL] [Abstract][Full Text] [Related]
19. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone.
Aihara Y; Ito R; Ito S; Aihara M; Yokota S
Pediatr Int; 2007 Oct; 49(5):659-62. PubMed ID: 17875095
[No Abstract] [Full Text] [Related]
20. Cyclosporine for SJS/TEN: a case series and review of the literature.
Reese D; Henning JS; Rockers K; Ladd D; Gilson R
Cutis; 2011 Jan; 87(1):24-9. PubMed ID: 21323097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
